LIMN · Liminatus Pharma, Inc.
$5.16
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.93M
Shares
1.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$10.21M
-187.8%
FY2025
Diluted EPS
-$21.50
-115%
FY2025
Operating Cash Flow
-$9.96M
-586.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| — | — | $2.69M | |
| $3.07M | $2.97M | $644.62K | |
| $4.07M | $2.97M | $3.33M | |
| -$4.07M | -$2.97M | -$3.33M | |
| $75.59K | $215.9K | $338.88K | |
| — | $76.59K | $122.53K | |
| -$8.46M | -$7.24M | -$216.36K | |
| -$12.52M | -$10.21M | -$3.55M | |
| USD/shares | — | -$21.50 | -$10.00 |
| USD/shares | — | -$21.50 | -$10.00 |
| shares | — | 475.07K | 350K |
| shares | — | 475.07K | 350K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.67×
EV/EBIT
—
Peer median 10.95×
P/E (TTM)
—
Peer medians compare against the 181 similar-size Biotechnology companies (of 546 listed).